Crisaborole
- EU EMA: by INN
- US DailyMed: Crisaborole
category
- AU: B1
administration
- D11AH06 (WHO)
- CA: ℞-only
- US: ℞-only
- EU: authorization withdrawn on request of pharmaceutical company
- In general: ℞ (Prescription only)
- 4-[(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile
- 906673-24-3
- 44591583
- DB05219
- 24701949
- Q2R47HGR7P
- D10873
- CHEBI:134677 Y
- ChEMBL484785
- DTXSID10238231
- Interactive image
- B1(c2ccc(cc2CO1)Oc3ccc(cc3)C#N)O
- InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2
- Key:USZAGAREISWJDP-UHFFFAOYSA-N
Crisaborole, sold under the brand name Eucrisa among others, is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in adults and children.[1][2][3][4]
The most common side effects are reactions at the application site (including burning or stinging).[3]
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known.[1][2]
Side effects
At the site of application, crisaborole may cause burning or stinging. Rarely, there may be an allergic reaction.[5]
Medical uses
In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older.[2]
In the EU, crisaborole was authorized for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.[3]
Pharmacology
Pharmacodynamics
Crisaborole is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation.[6] Chemically, crisaborole is a phenoxybenzoxaborole.[6] Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.[6]
People with atopic dermatitis produce high levels of proteins called cytokines, which can cause the inflammation of the skin seen in dermatitis.[3] Crisaborole blocks the release of certain cytokines involved in the inflammation process such as tumor necrosis factor alpha, interleukins (IL‑2, IL-4, IL-5), and interferon gamma.[3] By blocking their release, crisaborole is expected to ease the inflammation and therefore relieve symptoms of the disease.[3]
Chemistry
Crisaborole (chemical name: 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile) is a member of the class of benzoxaboroles characterized by the presence of a boronic acid hemiester with a phenolic ether and a nitrile.[7] Crisaborole crystallizes into two polymorphs that differ in the conformation of the oxaborole ring. A cocrystal with 4,4'-bipyridine has been prepared and studied by X-ray crystallography.[8]
History
Crisaborole was developed by Anacor Pharmaceuticals for the topical treatment of psoriasis.[9][6][10] During preclinical and clinical development, crisaborole was called AN2728 and PF-06930164.[11] The drug was assumed to be potential $2bn-a-year blockbuster, when Pfizer acquired Anacor Pharmaceuticals.[12] However, the drug was commercially not successful, reaching only US$147 million in sales in 2018, and US$138 million in sales in 2019.[13]
Crisaborole was approved for use in the United States in December 2016[14][1] and for use in Canada in June 2018.[15]
The safety and efficacy of crisaborole were established in two placebo-controlled trials with a total of 1,522 participants ranging in age from two years of age to 79 years of age, with mild to moderate atopic dermatitis.[1] In both trials participants received treatment with either crisaborole or placebo twice daily for 28 days.[16] Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed.[16] Overall, participants receiving crisaborole achieved greater response with clear or almost clear skin after 28 days of treatment.[1][16] The trials were conducted in the US.[16]
Crisaborole, approved for the treatment of mild to moderate atopic dermatitis in the European Union, has been rapidly withdrawn from the European market (March 2020 - February 2022).[3]
See also
- Tavaborole – a structurally related topical antifungal developed by Anacor
References
- ^ a b c d e "FDA Approves Eucrisa for Eczema" (Press release). U.S. Food and Drug Administration (FDA). 14 December 2016. This article incorporates text from this source, which is in the public domain.
- ^ a b c "Eucrisa- crisaborole ointment". DailyMed. 21 April 2020. Retrieved 28 April 2020.
- ^ a b c d e f g "Staquis EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 28 April 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ He Y, Liu J, Wang Y, Kuai W, Liu R, Wu J (6 February 2023). Pimpinelli N (ed.). "Topical Administration of Crisaborole in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis". Dermatologic Therapy. 2023: 1–9. doi:10.1155/2023/1869934. ISSN 1529-8019.
- ^ "PRODUCT MONOGRAPH" (PDF). Government of Canada. 7 June 2018. Archived (PDF) from the original on 7 April 2019. Retrieved 7 April 2019.
- ^ a b c d Moustafa F, Feldman SR (May 2014). "A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology" (PDF). Dermatology Online Journal. 20 (5): 22608. doi:10.5070/D3205022608. PMID 24852768.
- ^ "WHO Drug Information, Vol. 29, No. 3, 2015. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Information. p. 391. Retrieved 26 April 2016.
- ^ Campillo-Alvarado G, Didden TD, Oburn SM, Swenson DC, MacGillivray LR (2018). "Exploration of Solid Forms of Crisaborole: Crystal Engineering Identifies Polymorphism in Commercial Sources and Facilitates Cocrystal Formation". Crystal Growth & Design. 18 (8): 4416–4419. doi:10.1021/acs.cgd.8b00375. ISSN 1528-7483.
- ^ Nazarian R, Weinberg JM (November 2009). "AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis". Current Opinion in Investigational Drugs. 10 (11): 1236–42. PMID 19876791.
- ^ Spreitzer H (16 August 2016). "Neue Wirkstoffe: Crisaborol". Österreichische Apotheker-Zeitung (in German) (17/2016).
- ^ "Crisaborole". AdisInsight. Retrieved 24 July 2017.
- ^ "Pfizer to Acquire Anacor". Pfizer (Press release). 16 May 2016. Retrieved 28 April 2020.
- ^ "Pfizer Financial Report" (PDF). Pfizer. Retrieved 9 April 2020.
- ^ "Eucrisa (crisaborole) Ointment". U.S. Food and Drug Administration (FDA). 23 January 2017. Retrieved 28 April 2020.
- ^ "Eucrisa Regulatory Decision Summary". Health Canada. 23 October 2014. Archived from the original on 14 September 2019. Retrieved 14 September 2019.
- ^ a b c d "Drug Trials Snapshot: Eucrisa". U.S. Food and Drug Administration (FDA). 14 December 2016. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.
External links
- "Crisaborole". Drug Information Portal. U.S. National Library of Medicine.
- v
- t
- e
- Abrocitinib
- Aminobenzoate potassium
- Androgens (e.g., testosterone)
- Brimonidine
- Caffeine
- Calcium gluconate
- Collagen
- Crisaborole
- Cromoglicic acid
- Deoxycholic acid
- Diclofenac
- Dupilumab
- Estrogens (e.g., estradiol)
- Glycopyrronium tosylate
- Hyaluronic acid
- Hydrogen peroxide
- Ivermectin
- Magnesium sulfate
- Metandienone
- Oxymetazoline
- Pregnenolone acetate
- Progestogens (e.g., progesterone)
- Povidone-iodine
- Tiratricol
- Tralokinumab